The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
View original article
Contributor: Rebecca Robbins
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
View original article
Contributor: Rebecca Robbins